Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive clinical trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
The Lancet Neurology
Neuroscience
Platform
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial
June 1, 2025
2025
DOI: 10.1016/S1474-4422(25)00173-5
Brain Communications
Alzheimer's Disease
Neuroscience
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
May 30, 2025
2025
doi.org/10.1093/braincomms/fcaf210
Resuscitation Plus
Methodology
The California Resuscitation Outcomes Consortium (CAL-ROC): A novel collaboration to facilitate the implementation of randomized clinical trials in the prehospital setting
May 28, 2025
2025
DOI: 10.1016/j.resplu.2025.100992
Wiley Online Library
Neuroscience
Platform
Operational Development and Launch of an Adaptive Platform Trial in Amyotrophic Lateral Sclerosis: Processes and Learnings From the First Four Regimens of the HEALEY ALS Platform Trial. Muscle Nerve.
May 26, 2025
2025
DOI: 10.1002/mus.28442
Journal of Cardiac Failure
Methodology
Endpoints
Navigating Composite Endpoints: Methods and Recommendations for Trial Design and Interpretation
May 9, 2025
2025
DOI: 10.1016/j.cardfail.2025.04.008
Springer Nature
Infectious Disease
Meta-analysis
Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis
May 5, 2025
2025
DOI:10.1007/s00134-025-07912-2
Springer Nature
Infectious Disease
Platform
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial
April 22, 2025
2025
DOI: 10.1007/s00134-025-07861-w
The Journal of Infectious Diseases
COVID-19
Infectious Disease
A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration
April 1, 2025
2025
doi.org/10.1093/infdis/jiaf158
No results found.
There are no results with this criteria. Try changing your search.